Source comparison
The Evidence Gap: What We Know vs What We Don't
Every published BPC-157 TBI study to date uses animal models. Predominantly rats, with two studies using mice. The largest body of work comes from researchers at the University of Zagreb, who've published 15+ papers on BPC-157 across various injury models sinc
This comparison does not assign a generated winner or score.
- Every published BPC-157 TBI study to date uses animal models. Predominantly rats, with two studies using mice. The largest body of work comes from researchers at the University of Zagreb, who've published 15+ papers on BPC-157 across various injury models since the 1990s. Their 2018 traumatic brain injury paper showed reduced brain edema, improved Morris water maze performance (a spatial memory test), and faster restoration of normal gait patterns in treated rats compared to controls. Those outcomes are clinically relevant markers, but they're not human outcomes.
- No Phase I safety trial exists for BPC-157 in any indication, let alone concussion. That means we don't know the maximum tolerated dose in humans, we don't know the incidence or type of adverse events at therapeutic doses, and we don't know if repeated dosing causes accumulation or receptor desensitisation over time. The peptide has a favorable safety profile in animal studies. No reported mortality or organ toxicity even at supra-therapeutic doses. But extrapolating that to humans without controlled trials is scientifically unjustifiable.
- The absence of human data also means we don't know if BPC-157 would help concussion recovery at all, let alone whether it outperforms rest, cognitive rehabilitation, or other peptide candidates like cerebrolysin (which does have human TBI trial data, though results are mixed). The mechanistic rationale is sound, but mechanism alone doesn't predict clinical efficacy. Plenty of compounds with compelling preclinical profiles fail in Phase II trials because the biology is more complex than the model suggested.